# US 2023/0057076 A1 · Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057076 A1
- Document ID: US20230057076A1
- Status: Published application
- Kind: A1
- Application number: 17/897,961
- Filed: 2022-08-29
- Published: 2023-02-23
- Earliest claimed: 2018-03-15
- Assignees: Yale University
- Applicants: Yale University
- Inventors: William L. Jorgensen; Vinay Trivedi-Parmar
- Web page: https://patentgrep.com/patent/US20230057076A1

## CPC

- A61K 31/415: 1,2-Diazoles
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/16: Halogen atoms or nitro radicals
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating, ameliorating, and/or preventing inflammatory disease, neurological disorders and cancer using the compounds of the invention.

## Claims

### Claim 1

A compound of formula (I), or a salt, solvate, stereoisomer, or tautomer thereof, or any mixtures thereof:
wherein:
Y is selected from the group consisting of a bond, —CH2—, —O—, —S—, —S(═O)—, —S(═O)2, and —N(R2)—;
R1 is selected from the group consisting of H, C1-C6 alkyl, phenyl, naphthyl, tetrahydronaphthyl, phenanthryl, bicyclic heteroaryl, 1,2-dihydroacenaphthyl, acenaphthyl, adamantyl, (heteroaryl)-phenyl, and biphenyl;
R2 is selected from the group consisting of H and C1-C6 alkyl;
Z is selected from the group consisting of —C(═O)OR, —S(═O)R, —S(═O)2R, and —S(═O)2NRR;
X is selected from the group consisting of H, C1-C3 alkyl, and halogen;
wherein the phenyl, naphthyl, tetrahydronaphthyl, phenanthryl, bicyclic heteroaryl, 1,2-dihydroacenaphthyl, acenaphthyl, adamantyl, (heteroaryl)-phenyl, or biphenyl is independently optionally substituted with at least one group independently selected from the group consisting of halogen, —OH, —C(═O)OR, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, C3-C6 halocycloalkyl, C3-C6 halocycloalkoxy, —(CH2)1-6NRR, —O(CH2)1-6NRR, —(CH2)1-6NR(C1-C6 acyl), —O(CH2)1-6NR(C1-C6 acyl), —(CH2)1-6OR, —O(CH2)1-6OR, —(CH2)1-6C(═O)OR, —O(CH2)1-6C(═O)OR, —(CH2)1-6OR, —O(CH2)1-6OR, —(OCH2CH2)1-6NRR, and —(OCH2CH2)1-6C(═O)OR;
wherein each occurrence of R is independently selected from the group consisting of H and C1-C6 alkyl, or two R groups combine with the N atom to which they are both bound to form a 3-8 membered heterocyclyl or heteroaryl group; and
wherein, if R1—Y is H, then Z cannot be —C(═O)OH.

### Claim 2 (depends on 1)

The compound of claim 1, which is a compound of formula (6):

### Claim 3 (depends on 2)

The compound of claim 2, wherein R1 is selected from the group consisting of phenyl and naphthyl.

### Claim 4 (depends on 2)

The compound of claim 2, which is selected from the group consisting of:

### Claim 5 (depends on 1)

The compound of claim 1, which is a compound of formula (7):

### Claim 6 (depends on 5)

The compound of claim 5, wherein R1 is selected from the group consisting of phenyl and naphthyl.

### Claim 7 (depends on 5)

The compound of claim 5, wherein R2 is methyl.

### Claim 8 (depends on 5)

The compound of claim 5, which is selected from the group consisting of:

### Claim 9 (depends on 1)

The compound of claim 1, which is a compound of formula (8):

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is selected from the group consisting of methylphenyl, methoxyphenyl, fluorophenyl, ethylnapthyl, cyclopropylnaphthyl, methylbiphenyl, ethoxybiphenyl, and N-morpholinopropoxybiphenyl.

### Claim 11 (depends on 9)

The compound of claim 9, wherein X is fluorine.

### Claim 12 (depends on 9)

The compound of claim 9, which is selected from the group consisting of:

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 14 (depends on 1)

A method of treating or ameliorating an inflammatory disease, a neurological disorder, or cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the inflammatory disease is rheumatoid arthritis, Crohn's disease, or inflammatory bowel syndrome.

### Claim 16 (depends on 14)

The method of claim 14, wherein the neurological disorder is schizophrenia.

### Claim 17 (depends on 14)

The method of claim 14, wherein the cancer is colorectal, lung, breast, or prostate.

### Claim 18 (depends on 1)

A method of inhibiting macrophage migration inhibitory factor in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 1.

### Claim 19 (depends on 1)

A method of treating or ameliorating a disease or disorder associated with upregulated and/or dysregulated macrophage migration inhibitory factor expression in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 1.
